Bring the objection and the revised inference into the conversation.

I would start with my 2008 classification of nine brands and the later finding that six shared one institutional procurement route. The proposed discussion would retain Camille Dervelune’s challenge, the colleagues’ defence of genuine product differences and C$620,000 in research and correction expense. Participants would examine what a count establishes and which further relationships matter to a particular strategic choice. I would distinguish a commercial dependency from a professional judgement about a medicine, keeping the latter with qualified owners. The session would not offer a preferred number of brands or suggest that common procurement is automatically undesirable. A real event would use authorised material and verified definitions, with counterpart confidentiality preserved. The purpose would be to show how a leader can acknowledge an incomplete inference and use the correction constructively, without rewriting the original mistake as someone else’s problem or presenting a portfolio chart as a complete account of institutional exposure.

I would examine the fictional two-market proposal whose model placed 56% of C$135 million annual sales at maturity through one distribution group. The sponsors’ argument for joint preparation would receive the same attention as my recommendation to prepare one market first. The proposed session would keep C$2.4 million expense and the lost simultaneous momentum visible. It would distinguish geography, commercial route and the professional conditions for the actual business. I would not present the modelled sales as a result, assess product permissions or prescribe a general market-entry sequence. Participants would consider how a presentation can show both the benefit of a concentrated relationship and the dependence it creates. A real discussion would require permitted examples and current professional context. The contribution would be a more precise way to describe the undertaking being chosen, rather than an assertion that a smaller first step is necessarily safer or that every wider map represents independent exposure.

I would separate the invented portfolio’s nine early development activities from its five established-medicine extensions and examine why the original shared format made comparison too easy. The proposed discussion would preserve the early sponsors’ concern that their work might lose strategic attention. C$1.3 million in analysis expense and the extra effort of communicating a qualified account would remain part of the case. Participants would consider which conclusions a total count can support and which require specialist interpretation. I would not assign clinical probabilities, values or regulatory outcomes. Scientific, medical, financial and other professional authorities would remain explicit. An actual seminar would need authorised evidence and appropriate expertise for any live questions. The intended result is a clearer conversation about ambition and uncertainty, where early work can be taken seriously on its own terms instead of being excluded from the strategy or made to resemble an established business before its evidence allows that description.

I would use the fictional smaller portfolio’s C$26 million annual revenue and C$4.2 million support estimate to examine the interval between considering an option and completing a change. The discussion would retain the disposal argument and the management attention that continued planning required. It would not subtract the support estimate from revenue into a margin or imply that a strategist can determine medical, quality, safety or regulatory responsibilities. Participants would ask how an institution keeps present work visible while it reviews a different future. A real workshop would require the relevant professional context and permission to use any operational examples. This is proposed speaking material, not a record of a delivered engagement. Its aim would be to make a strategic account more complete about a smaller activity, including uncertainty and continuing expense, without promising a transaction outcome or treating a possible future transfer as if it had already changed the company’s responsibilities.